UCB CEO Doliveux pledges to provide clear path for his successor
This article was originally published in Scrip
With the clock ticking down to his retirement, UCB CEO Roch Doliveux revealed two pledges he is making to his successor Jean-Christophe Tellier who is due to take over the reins 1 January 2014. He has promised not to be a "mother-in-law" providing unwanted advice and looking over Mr Tellier's shoulder but has pledged over the next 10 months to continue developing the business to allow him to be more successful.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.